DOI: 10.1097/01.COT.0000291760.64285.be
,
Issn Print: 0276-2234
Publication Date: 2006/09/10
Facebook
Twitter
LinkedIn
Email
 |
Checking for direct PDF access through Ovid | |
Excerpt
The protein, IMP3 (IMP stands for insulin—like growth factor messenger—RNA binding protein), could be used to select patients who would most likely benefit from adjuvant treatment if the results are confirmed in a prospective clinical trial, said lead author Zhong Jiang, MD, Director of Urologic Pathology at the University of Massachusetts Medical School.
While variables such as tumor stage, grade, histology, and necrosis are currently used to assess a patient's risk of metastasis, prognosis can still prove elusive, particularly with early—stage disease.
“When people go for cancer surgery and they have clinically—only evidence of localized disease, we know in kidney cancer that somewhere between 10 percent and even up to 50 percent of patients can develop metastatic disease in the future,”said Allan Pantuck, MD, Associate Professor of Urology at the David Geffen School of Medicine at UCLA, who was not involved with the study.
“We have limited tools to help us predict who those people are. Any biomarker, any technique that could help refine our ability to predict the patients who are at most risk would be helpful.
